1 / 30

Dr Muhammad J Motiwala MD, FACP, Al Mafraq Hospital Abu Dhabi-UAE

Recent Update In The Management Of Invasive Candidiasis. Dr Muhammad J Motiwala MD, FACP, Al Mafraq Hospital Abu Dhabi-UAE. Overview. Invasive Fungal Infections Antifungal Agents Polyenes Azoles Glucan Synthesis Inhibitors IDSA Treatment Guidelines. Review of our Fungal “Players”.

osric
Download Presentation

Dr Muhammad J Motiwala MD, FACP, Al Mafraq Hospital Abu Dhabi-UAE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Recent Update In The Management Of Invasive Candidiasis Dr Muhammad J MotiwalaMD, FACP,Al Mafraq HospitalAbu Dhabi-UAE

  2. Overview • Invasive Fungal Infections • Antifungal Agents • Polyenes • Azoles • Glucan Synthesis Inhibitors • IDSA Treatment Guidelines

  3. Review of our Fungal “Players” • Opportunistic fungi • Normal flora • Candida spp. • Ubiquitous in our environment • Aspergillus spp. • Cryptococcus spp. • Mucor spp. • Endemic geographically restricted • Blastomyces sp. • Coccidioides sp. • Histoplasma sp. • Newly emerging fungi • Fusarium • Scedosporidium • Trichosporin

  4. Rank order of nosocomial bloodstream pathogens and their associated mortality

  5. Predisposing Factors to Fungal Infections (IFI) • Broad spectrum antibiotics • Immunosuppression • Corticosteroids • Prolonged hospitalization (ICU Stay) • TPN (intravascular catheter use) • Prolonged neutropenia • Hemodialysis /Acute Renal Failure • Diabetes Mellitus • Mechanical Ventilation • Recent gastrointestinal / Cardiac surgery • Burns • Colonization

  6. Incidence of Invasive Fungal Infections • Solid Organ Transplant 5 - 42% • Kidney 5 – 14% • Heart 5 – 32% • Heart-Lung/Lung 15 – 36% • Pancreas 18 – 38% • Liver 7 – 42 % • Bone Marrow Transplant 15 - 25% • Intensive Care Unit 17% Singh, N. CID 2000; 31:545-53 Vincent JL. Intensive Care Med 1998; 24: 206-216

  7. MortalityRates • Candidemia has a mortality rate of ~40%. • Invasive aspergillosis continues to be a highly lethal opportunistic infection: • 375% increase in mortality due to Aspergillus species from 1980 to 1997. • Overall mortality rate in patients with invasive aspergillosis is reported to be 58%. • Mortality continues to be high regardless of the antifungal therapy used. Edmond MB et al. CID 1999;29:239-44. National Center for Health Statistics (1980-1997) Lin S et al. CID 2001;32:358-66.

  8. Challenges • Delaying antifungal therapy until blood cultures are positive is associated with increased mortality • Diagnostic limitations

  9. Clinical approaches to assess risk • Fungal colonizing index: the greater the number of positive sites, the greater the increased risk for invasive infection • Combine colonization with other risk factors: surgery on admission, TPN, and sepsis • No colonisation index but include variables: ≥ 4 days in ICU, CVC, DM, new hemodialysis, TPN, and broad-spectrum antibiotics Pittet D. Ann Surg. 1994;220:751-758. Paphitou NI. Med Mycol. 2005;43:235-243

  10. Colonization in ICU patients • Prevalence of colonization in ICU is high (50% to 70% or more) compared with relatively low rate of infection, so predictive value of colonization is poor • However colonisation with unexplained fever, leukocytosis, and hypotension  may indicate invasive candidiasis Ostrosky-Zeichner L. Crit Care Med. 2006;34:857-863 Eggimann P. Lancet Infect Dis. 2003;3:685-702

  11. Which antifungal to choose? • Candida speciation may take up to 5 days • and fluconazole susceptibility testing may take an additional 5 days

  12. Targetedanti-fungal therapyThe “challenging” wisdom Withhold Antifungal therapy unless positive diagnostic test Advantages Directed therapy, ?less cost, less anti-fungal toxicity Disadvantages Variable sensitivity and specificity diagnostic tests Unproven benefit in reducing mortality, ?costs

  13. Treatment options of invasive fungal infections in adults.Swiss Med Wkly. 2006 Jul 22;136(29-30):447-63

  14. Spellberg BJ et al. Clin Infect Dis. 2006 Jan 15;42(2):244-51

  15. Diagnostic Dilemma Clinical Setting: with other risk factors Radiology: applicable more for Aspergillus Cultures: Low yield and longer time Staining: GMS and Calcofluor white PCR Assay: not widely available 1-3 Beta Glucan Assay: Galactomannan Assay: For Aspergillus PNA FISH:

  16. PNA FISH: Clinical Benefits Summary 5 October 2014 • Rapid and accurate identification of bloodstream pathogens direct from positive blood cultures • Simple to implement and easy to use • Maintains species morphology • Actionable PNA FISH results for 95% of BC+ • Development of new therapeutic guidelines • Improved patient safety • Early appropriate and effective antibiotic therapy • Reduction in mortality • Reduction in unnecessary antimicrobial and antifungal use • Reduction in hospital length of stay (LOS) • Significant cost savings 23

  17. Antifungal choice Organism (proven, suspected) Site of disease Host factors (eg age, neutropenia, mucositis) History of antifungal therapy and/or prophylaxis Tolerability/ side effects Drug-Drug interactions Costs

  18. ANTI FUNGAL AGENTS

  19. Antifungal Drug Development 1950s 1960s 1970s 1980s 1990s 2000s Griseofulvin Ketaconazole Fluconazole Itraconazole Terbinafine AMB lipid Formulations Itraconazole Itra (IV) Caspofung Voricon Micafung Anidulofung Posacon Ravucon Econazole, miconazole(IV) AMBd 5FC miconazole (top) clotrimazole (top)

  20. Antifungal agents • Polyenes (cell membrane) • Conventional Amphotericin B • Lipid formulations • Ambisome, Abelcet, Amp B Colloidal Dispersion • Triazoles (sterol synthesis) • Fluconazole, Itraconazole, Voriconazole, Posaconazole • Ravuconazole • Echinocandins (cell wall) • Caspofungin • Anidulofungin, Micafungin • Allyamines (sterol synthesis) • Terbinafine

  21. Biochemical Targets for Antifungal Chemotherapy Arrangement of the biomolecular components of the cell wall accounts for the individual identity of the organism. Although, each organism has a different biochemical composition, their gross cell wall structure is similar. Antifungal agents targeted towards: Inhibition of fungal cell wall synthesis – caspofungin is a -glucan synthesis inhibitor; several more compounds are under investigation Inhibition of fungal cell membrane synthesis – ergosterol is the target (cell membranes of fungi and mammals contain different sterols): polyenes, azoles, triazoles, alkylamines Inhibition of cell division – microtubule effects: griseofulvin; DNA: flucytosine.

  22. Antifungal Agents- Sites of action Echinocandins Inhibit fungal cell wall biosynthesis Griseofulvin Inhibits mitotic spindle formation

  23. B-1,3 Glucan Synthase Caspofungin B-1,6 Glucan B-1,3 Glucan Phospholipid Bilayer Cell Wall AMB Ergosterol Zymosterol 14 Me-fecosterol Lanosterol Azoles Azoles Terbinafine Squalene

More Related